Profile data is unavailable for this security.
About the company
Oncimmune Holdings plc is a United Kingdom-based company, which is engaged in the autoantibody profiling to the pharmaceutical and biotechnology industry. The Company primarily focused on the growing fields of immuno-oncology, autoimmune disease, and infectious diseases. The Company's principal activity is the development and commercialization of technologies that enable cancer diagnosis. Its service offerings include ImmunoINSIGHTS. The ImmunoINSIGHTS service business leverages its technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Its immune-profiling technology helps the Company in identifying trial participants and patients into clinically relevant subgroups, which enables the development of targeted treatments. The Company's subsidiary is Oncimmune Germany GmbH.
- Revenue in GBP (TTM)1.21m
- Net income in GBP-3.14m
- Incorporated2015
- Employees33.00
- LocationOncimmune Holdings PLC1 Park RowLEEDS LS1 5ABUnited KingdomGBR
- Phone+44 115 823 1869
- Fax+44 115 823 1958
- Websitehttps://www.oncimmune.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N4 Pharma PLC | 5.86k | -1.12m | 2.37m | 5.00 | -- | 1.89 | -- | 404.21 | -0.0042 | -0.0042 | 0.00002 | 0.0032 | 0.0041 | -- | 0.0421 | 1,172.00 | -79.19 | -57.05 | -83.28 | -61.13 | -- | -- | -19,152.56 | -309,312.80 | -- | -3,023.17 | 0.00 | -- | -- | -51.52 | -24.05 | -- | -- | -- |
CRISM' Therapeutics Corp | 0.00 | -349.70k | 3.10m | 4.00 | -- | 1.50 | -- | -- | -0.0408 | -0.0408 | 0.00 | 0.0634 | 0.00 | -- | -- | 0.00 | -8.18 | -8.91 | -12.38 | -9.27 | -- | -- | -- | -- | -- | -1.01 | 0.00 | -- | -- | -- | 9.04 | -- | -- | -- |
BSF Enterprise PLC | 67.24k | -1.71m | 4.13m | 4.00 | -- | 1.03 | -- | 61.47 | -0.0166 | -0.0166 | 0.0007 | 0.0387 | 0.0128 | 1.79 | 0.0425 | 16,810.00 | -32.47 | -- | -34.78 | -- | -44.74 | -- | -2,542.56 | -- | 6.17 | -218.85 | 0.0287 | -- | -- | -- | -61.40 | -- | -- | -- |
Kanabo Group PLC | 1.14m | -8.18m | 6.96m | 17.00 | -- | 1.17 | -- | 6.10 | -0.013 | -0.013 | 0.0018 | 0.0094 | 0.1054 | 16.28 | 43.85 | 67,058.82 | -75.70 | -75.83 | -81.16 | -83.33 | 7.89 | -- | -718.33 | -1,267.35 | 2.72 | -63.43 | 0.0337 | -- | 48.42 | -- | -16.26 | -- | -- | -- |
Oncimmune Holdings PLC | 1.21m | -3.14m | 11.79m | 33.00 | -- | -- | -- | 9.71 | -0.0423 | 0.0958 | 0.0164 | -0.0172 | 0.1756 | 1.19 | 0.6917 | 36,787.88 | -45.43 | -- | -- | -- | 63.34 | -- | -258.65 | -- | 1.01 | -0.6511 | 1.32 | -- | -- | -- | -- | -- | -- | -- |
Celadon Pharmaceuticals PLC | 130.00k | -5.23m | 22.37m | -- | -- | 8.82 | -- | 172.11 | -0.0827 | -0.0827 | 0.002 | 0.0368 | 0.0145 | 26.79 | 0.1194 | -- | -58.39 | -- | -67.06 | -- | -3,433.85 | -- | -4,024.62 | -- | 1.56 | -8.76 | 0.6608 | -- | 212.50 | -- | 58.01 | -- | -- | -- |
CRUSHMETRIC Group Ltd | 865.43k | -6.56m | 30.03m | 20.00 | -- | 1.66 | -- | 34.69 | -0.0233 | -0.0233 | 0.0033 | 0.0752 | 0.0328 | 6.13 | 15.64 | -- | -25.27 | -25.22 | -31.29 | -56.66 | 73.06 | 41.64 | -771.01 | -200.76 | 0.0273 | -3.18 | 0.0802 | -- | -36.42 | -8.40 | -1,096.05 | -- | -29.47 | -- |
Eco Animal Health Group Plc | 89.42m | 1.05m | 48.10m | 222.00 | 50.25 | 0.5747 | 10.01 | 0.5379 | 0.0141 | 0.0141 | 1.29 | 1.24 | 0.7312 | 2.63 | 2.98 | 402,801.80 | 1.64 | 4.56 | 2.29 | 6.22 | 42.14 | 45.40 | 2.25 | 5.92 | 2.29 | 7.46 | 0.0413 | 5.37 | 4.82 | 5.86 | 3.97 | -32.08 | 2.71 | -- |
Venture Life Group PLC | 51.41m | 742.00k | 57.81m | 165.00 | 116.07 | 0.7752 | 5.97 | 1.12 | 0.0039 | 0.0039 | 0.3847 | 0.5869 | 0.4453 | 2.67 | 3.92 | 311,575.80 | 0.6427 | 1.58 | 0.7172 | 1.83 | 39.62 | 40.14 | 1.44 | 3.99 | 1.42 | 2.16 | 0.2215 | 0.00 | 16.89 | 22.33 | 77.12 | 31.30 | 18.85 | -- |
Holder | Shares | % Held |
---|---|---|
Hargreaves Lansdown Asset Management Ltd.as of 31 Aug 2023 | 3.14m | 4.23% |
Chelverton Asset Management Ltd.as of 31 Aug 2023 | 3.01m | 4.06% |
Unicorn Asset Management Ltd.as of 31 Jul 2024 | 1.16m | 1.57% |
Gabelli Funds LLCas of 28 Mar 2024 | 2.90k | 0.00% |